Introduction {#sec1}
============

It is well known that human CYP24A1 plays an important role in the specific metabolism of 25-hydroxylated vitamin D~3~ \[25(OH)D~3~\] consisting of the 23-position and 24-position hydroxylation pathways that degrade the side chain ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref1]^ The 3-step oxidation after the C23 hydroxylation of 25(OH)D~3~ leads to the production of 25(OH)D~3~-26,23-lactone. On the other hand, the 24-hydroxylation pathway of 25(OH)D~3~ produces calcitroic acid.^[@ref2]^

![Metabolic Pathways of 25-Hydroxyvitamin D~3~ \[25(OH)D~3~\] by Human CYP24A1^[@ref1]^](ao-2019-01500b_0002){#sch1}

To increase the chemical or metabolic stability against CYP24A1, fluorine-substituted vitamin D~3~ analogues have been actively synthesized.^[@ref3]−[@ref7]^ For example, falecalcitriol (**1**) has longer duration of action in vivo, and it was approved for the treatment of secondary hyperparathyroidism and hypoparathyroidism in Japan. Therefore, we focused on the importance of the fluorinated vitamin D~3~ analogues and demonstrated an efficient synthetic methodology to introduce fluorine atoms to the side chain of vitamin D~3~.^[@ref8]^ On the 25(OH)D~3~ side chain, the C23 position is one of the important catabolic sites of CYP24A1. However, to the best of our knowledge, only a few C23-fluorinated vitamin D~3~ analogues have been synthesized thus far. The first report on C23-fluorinated vitamin D~3~ analogues was the synthesis of 23,23-difluoro-25-hydroxyvitamin D~3~ \[23,23-F~2~-25(OH)D~3~ (**2**)\] published by Kobayashi's group in 1984.^[@ref9]^ After that, Ikeda and colleagues reported (23*R*)-23,26,26,26,27,27,27-heptafluoro-1α,25-dihydroxyvitamin D~3~ \[(23*R*)-23,26,26,26,27,27,27-F~7~-1α,25(OH)~2~D~3~\] (**3**) and its 23*S* isomer \[(23*S*)-23,26,26,26,27,27,27-F~7~-1α,25(OH)~2~D~3~\] (**4**) in 2000.^[@ref10]^ We have developed a novel practical approach to (23*R*)-23-fluoro-25-hydroxyvitamin D~3~ \[(23*R*)-23-F-25(OH)D~3~\] (**5**) and its 23*S* isomer \[(23*S*)-23-F-25(OH)D~3~\] (**6**) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), and clarified their biological activity, especially CYP24A1 metabolic resistance.

![Structures of vitamin D~3~ analogues with the fluorinated side chain **1**--**4** and the new analogues **5** and **6**. Falecalcitriol (**1**), 23,23-F~2~-25(OH)D~3~ (**2**), (23*R*)-23,26,26,26,27,27,27-F~7~-1α,25(OH)~2~D~3~ (**3**), and (23*S*)-23,26,26,26,27,27,27-F~7~-1α,25(OH)~2~D~3~ (**4**), (23*R*)-23-F-25(OH)D~3~ (**5**), and (23*S*)-23-F-25(OH)D~3~ (**6**).](ao-2019-01500b_0001){#fig1}

Results and Discussion {#sec2}
======================

The synthetic plan for analogues (**5**,**6**) is described in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. Stereoselective introduction of the fluorine atom would be performed by deoxy-fluorination using *N*,*N*-diethylaminosulfur trifluoride (DAST) or 2-pyridinesulfonyl fluoride (PyFluor). Triene structures would be constructed by the Wittig--Horner coupling reaction between the CD-ring precursors (**7**,**8**) and the lithium salt of the A-ring anion from phosphine oxide **9**.^[@ref11]^

![Retrosynthetic Analysis of 23-Fluoro-25-hydroxyvitamin D~3~ (**5** and **6**)](ao-2019-01500b_0003){#sch2}

The synthesis of CD-ring precursors **7** and **8** using PyFluor is shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"} (method A). The aldehyde **10** was synthesized in 4 steps by the established method from Inhoffen--Lythgoe diol.^[@ref12]^ Introduction of the hydroxy group to C23 was accomplished by the aldol reaction with ethyl acetate, and the 25-hydroxy group was consequently constructed by Grignard reaction to provide diols **11** and **12**.^[@ref1]^ These two alcohols were separated by silica-gel column chromatography. Stereoselective deoxy-fluorination to the secondary hydroxy group (23-OH) of **11** and **12** was successfully performed by PyFluor to give **13** (from **12**) and **14** (from **11**) in moderate yields, without interfering with the tertiary hydroxy group (25-OH).^[@ref13]^ Deprotection of the TES group gave alcohols **15** and **16**. Tetrapropylammonium perruthenate (TPAP) oxidation followed by trimethylsilylation of the 25-OH group gave ketones **7** and **8**, respectively.

![Synthesis of CD-ring Precursors (**7** and **8**) Using PyFluor (Method A)](ao-2019-01500b_0004){#sch3}

Next, we tried to improve the yield of the deoxy-fluorination step in [Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"} (method B). As we mentioned above, the yield of stereoselective deoxy-fluorination using PyFluor was relatively low, especially in the case of 23*S*,25-diol (**12**). As shown in [Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}, another synthetic route to improve the yield of the CD-ring precursor (**15**) was developed. The synthetic intermediate in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}, aldehyde **10**, was reacted with 2-methylallylmagnesium chloride to give a diastereomeric mixture of homoallylic alcohols **17** and **18**.^[@ref1]^ Diastereomers **17** and **18** were separated by silica gel column chromatography, and **17** was treated with mCPBA to give epoxide **19**. Then, **19** was applied to stereoselective deoxy-fluorination using DAST. The reaction time became shorter and the yield of the desired fluorinated epoxied **20** was improved. Reductive opening of the epoxide progressed using LiAlH~4~, and subsequent desilylaiton provided **15**.

![Alternative Synthetic Route for (23*R*)-23-Fluorinated CD-ring Precursor **15** (Method B)](ao-2019-01500b_0005){#sch4}

The coupling reactions of **7** and **8** with carbanion of the A-ring precursor **9** and subsequent deprotection of the silyl ether group resulted in (23*R*)-23-F-25(OH)D~3~ (**5**) and (23*S*)-23-F-25(OH)D~3~ (**6**) in 68 and 43% yields, respectively ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}).

![Wittig--Horner Reaction, and Deprotection Steps for **5** and **6**](ao-2019-01500b_0006){#sch5}

Metabolic studies of **5** and **6** were performed using a reconstituted system containing recombinant human CYP24A1. The metabolites of each analogue were analyzed by reversed-phase HPLC, and their kinetic parameters were estimated ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

###### Kinetic Parameters of Human CYP24A1 for 25(OH)D~3~ and Its Two Analogues

  substrate                 *k*~cat~ (min^--1^)   *K*~m~ (μM)   *k*~cat~/*K*~m~
  ------------------------- --------------------- ------------- -----------------
  25(OH)D~3~                15.3 ± 4.5            0.76 ± 0.21   20.1
  (23*R*)-23-F-25(OH)D~3~   7.8 ± 2.1             0.39 ± 0.13   20.0
  (23*S*)-23-F-25(OH)D~3~   2.1 ± 0.5             0.38 ± 0.13   5.5

The *k*~cat~/*K*~m~ value of CYP24A1 for (23*R*)-23-F-25(OH)D~3~ (**5**) was similar to that for 25(OH)D~3~, whereas that for (23*S*)-23-F-25(OH)D~3~ (**6**) was approximately 4 times lower than that for 25(OH)D~3~. These results suggested that (23*S*)-23-F-25(OH)D~3~ (**6**) is more resistant to CYP24A1-dependent metabolism than both 25(OH)D~3~ and (23*R*)-23-F-25(OH)D~3~ (**5**).

Conclusions {#sec3}
===========

A new method to synthesize 23-fluorinated vitamin D~3~ analogues was developed. Introduction of a fluorine atom to the C23-position was accomplished by deoxy-fluorination using PyFluor or DAST in a stereoselective manner. We presented two synthetic routes to construct CD-ring precursors (**7** and **8**), and the subsequent Wittig--Horner reaction with A-ring (**9**) produced the target compounds (**5** and **6**). The CD-ring precursors (**7** and **8**) may aid in the preparation of new 23-fluorinated vitamin D~3~ analogues. Kinetic studies on the metabolism of **5** and **6** revealed that the stereochemistry at the C23-F position significantly affects the resistance to human CYP24A1. These results suggest that **5** may have more potent biological effects than 25(OH)D~3~.

Experimental Section {#sec3.1}
--------------------

### General Information {#sec3.1.1}

^1^H NMR (internal tetramethylsilane (TMS) as reference): 400 MHz (CDCl~3~ or CD~3~OD) with JEOL AL-400 NMR and 600 MHz (CDCl~3~) with JEOL ECP-600. ^13^C NMR (deuterated solvent, δ 77.0 ppm for CDCI~3~ or 49.3 ppm for CD~3~OD, as reference): 100 MHz (CDCl~3~ or CD~3~OD) with JEOL AL-400 NMR and 150 MHz (CDCl~3~) with JEOL ECP-600. IR: JASCO FT-lR-800 Fourier transform infrared spectrophotometer. HRMS: SHIMADZU LCMS-lT-TOF mass spectrometer with a positive electrospray ionization (ESl) method. Optical rotations: JASCO DIP-370 digital polarimeter. Flash column chromatography: silica gel 60N (Kanto Chemical Co., lnc., 40--50 μm) or silica gel 60 (Merck, 0.040--0.063 mm). Preparative thin-layer chromatography: precoated silica gel 60 F~254~ (Merck, 0.5 mm). Experiments were performed under argon, unless otherwise stated.

### (4*R*,6*R*)-4-Fluoro-2-methyl-6-{(1*R*,3*aR*,4*S*,7*aR*)-7*a*-methyl-4-\[(triethylsilyl)oxy\]octahydro-1*H*-inden-1-yl}heptan-2-ol (**13**) {#sec3.1.2}

To the toluene solution (166 μL) of **12**([@ref1]) (34.3 mg, 0.083 mmol) and DBU (25.3 mg, 25 μL, 0.17 mmol), PyFluor (16.1 mg, 0.10 mmol) was added, and the reaction mixture was stirred at room temperature (rt) for 90 h. To quench the reaction, water was added to the mixture at rt, and the mixture was extracted with ethyl acetate three times. The organic layer was dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residue by flash column chromatography (hexane/ethyl acetate = 6:1) gave **13** (7.6 mg, 22%) as a colorless oil.

**13**: \[α\]~D~^27^ +45.4 (c 0.81, CHCl~3~); IR (neat) 3401, 1458, 1377, 1165, 1084, 1035, 738 cm^--1^; ^1^H NMR (400 MHz, CDCl~3~) δ 0.55 (q, *J* = 8.3 Hz, 6H), 0.93--1.34 (m, 30H), 1.49--1.99 (m, 8H), 4.03 (dd, *J* = 2.3, 4.9 Hz, 1H), 4.86--5.04 (m, 1H); ^13^C NMR (100 MHz, CDCl~3~) δ 4.9, 6.9, 13.5, 17.7, 18.7, 23.0, 27.3, 29.7, 29.9, 31.6 (d, *J* = 5.7 Hz), 34.6, 40.8, 42.3, 42.7 (d, *J* = 21.0 Hz), 48.7 (d, *J* = 18.2 Hz), 53.1, 57.1, 69.4, 70.2, 90.2 (d, *J* = 163.1 Hz); HRMS (ESI^+^) calcd for C~24~H~47~FO~2~Si \[M + Na\]^+^ 437.3227, found 437.3211.

### (4*S*,6*R*)-4-Fluoro-2-methyl-6-{(1*R*,3*aR*,4*S*,7*aR*)-7*a*-methyl-4-\[(triethylsilyl)oxy\]octahydro-1*H*-inden-1-yl}heptan-2-ol (**14**) {#sec3.1.3}

PyFluor (946.3 mg, 5.87 mmol) was added to the solution of **11**([@ref1]) (1.84 g, 4.46 mmol) and DBU (1.36 g, 1.33 mL, 8.92 mmol) in toluene (10.4 mL), and the mixture was stirred at rt for 1 day. To quench the reaction, water was added to the mixture at rt, and the mixture was extracted with ethyl acetate three times. The organic layer was dried over Na~2~SO~4~, filtered, and concentrated in vacuo. The residual oil was roughly purified by flash column chromatography (hexane/Et~2~O = 2:1), followed by repurification by flash column chromatography (hexane/Et~2~O = 3:1) to obtain **14** (1.02 g, 55%) as a colorless oil.

**14**: \[α\]~D~^27^ +41.2 (c 1.05, CHCl~3~); IR (neat) 3410, 1459, 1376, 1166, 1085, 1025, 739 cm^--1^; ^1^H NMR (600 MHz, CDCl~3~) δ 0.55 (q, *J* = 7.2 Hz, 6H), 0.91 (s, 3H), 0.93--0.97 (m, 12H), 1.07--1.72 (m, 19H), 1.78--1.85 (m, 3H), 1.94 (dt, *J*~(t)~ = 3.6 Hz, *J*~(d)~ = 12.6 Hz, 1H), 4.03 (dd, *J* = 3.0, 4.5 Hz, 1H), 4.86--4.99 (m, 1H); ^13^C NMR (150 MHz, CDCl~3~) δ 4.9, 6.9, 13.5, 17.7, 19.2, 23.0, 27.6, 29.5, 30.0, 33.5 (d, *J* = 5.7 Hz), 33.6, 40.8, 42.1 (d, *J* = 18.6 Hz), 42.2, 47.9 (d, *J* = 18.8 Hz), 53.0, 57.1, 69.3, 70.2, 92.5 (d, *J* = 160.8 Hz); HRMS (ESI^+^) calcd for C~24~H~47~FO~2~Si \[M + Na\]^+^ 437.3227, found 437.3234.

### (1*R*,3*aR*,4*S*,7*aR*)-1-\[(2*R*,4*R*)-4-Fluoro-6-hydroxy-6-methylheptan-2-yl\]-7*a*-methyloctahydro-1*H*-inden-4-ol (**15**) {#sec3.1.4}

#### Method A {#sec3.1.4.1}

To the MeOH solution (5 mL) of **13**, *p*-toluenesulfonic acid monohydrate (95.1 mg, 0.5 mmol) was added, and the reaction mixture was stirred at rt for 15 min. To quench the reaction, water and sat. NaHCO~3~ aq. were added to the mixture at rt, and it was extracted with ethyl acetate three times, washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. The residual oil was purified by flash column chromatography (hexane/ethyl acetate = 2:1) to yield **15** (39.2 mg, 81%) as a colorless oil.

#### Method B {#sec3.1.4.2}

To the CH~2~Cl~2~ solution (3 mL) of **17**([@ref1]) (103.2 mg, 0.26 mmol) and NaHCO~3~ (642.4 mg, 7.65 mmol), mCPBA (87.8 mg, 0.51 mmol) was added at 0 °C, and it was stirred at the same temperature for 1 h. Water and sat. NaHCO~3~ aq. were added to the reaction mixture at rt, and it was extracted with CH~2~Cl~2~ three times, washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residue by flash column chromatography (hexane/ethyl acetate = 5:1) gave the crude product **19**. To the CH~2~Cl~2~ solution (4 mL) of the crude product **19**, DAST (95.1 mg, 0.5 mmol) was added at −78 °C, and the reaction mixture was stirred at the same temperature for 15 min. To quench the reaction, water and sat. NaHCO~3~ aq. were added to the reaction mixture at rt, and the mixture was extracted with CH~2~Cl~2~ three times, washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. The residual oil was purified by flash column chromatography (hexane/ethyl acetate = 10:1) to yield the crude fluoro-epoxide **20**. To the THF solution (3 mL) of the crude **20**, LiAlH~4~ (14.0 mg, 0.37 mmol) was added at 0 °C, and the reaction mixture was stirred at the same temperature for 1 h. After MeOH was added to the mixture, water and sat. potassium sodium tartrate aq. were added, successively. The mixture was extracted with ethyl acetate three times, washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. The residual oil (crude **13**) was used for the next step without further purification. To the MeOH solution (5 mL) of the crude **13**, *p*-toluenesulfonic acid monohydrate (100.6 mg, 0.53 mmol) was added, and the reaction mixture was stirred at rt for 15 min. To quench the reaction, water and sat. NaHCO~3~ aq. were added to the reaction mixture at rt, successively, and the mixture was extracted with ethyl acetate three times. The organic layer was washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residue by flash column chromatography (hexane/ethyl acetate = 1:1) gave **15** (30.0 mg, 37%, 4 steps) as a colorless oil.

**15**: \[α\]~D~^27^ +27.7 (c 0.50, CHCl~3~); IR (neat) 3364, 1470, 1381, 1166, 1147, 981, 871 cm^--1^; ^1^H NMR (600 MHz, CDCl~3~) δ 0.96 (s, 3H), 0.98 (d, *J* = 6.0 Hz, 3H), 0.99--1.11 (m, 2H), 1.14--1.20 (m, 1H), 1.25--1.36 (m, 2H), 1.28 (s, 3H), 1.31 (s, 3H), 1.42--1.73 (m, 8H), 1.80--1.95 (m, 5H), 2.01--2.03 (m, 1H), 4.07--4.08 (m, 1H), 4.89--5.02 (m, 1H); ^13^C NMR (150 MHz, CDCl~3~) δ 13.5, 17.4, 18.6, 22.5, 27.2, 29.8 (d, *J* = 12.9 Hz), 31.6, 33.6, 40.4, 42.0, 42.6 (d, *J* = 21.6 Hz), 48.7 (d, *J* = 18.6 Hz), 52.6, 56.9, 69.3, 70.2, 90.1 (d, *J* = 163.7 Hz); HRMS (ESI^+^) calcd for C~18~H~33~O~2~F \[M + Na\]^+^ 323.2357, found 323.2361.

### (1*R*,3*aR*,4*S*,7*aR*)-1-\[(2*R*,4*S*)-4-Fluoro-6-hydroxy-6-methylheptan-2-yl\]-7*a*-methyloctahydro-1*H*-inden-4-ol (**16**) {#sec3.1.5}

To the MeOH solution (10 mL) of **14**, *p*-toluenesulfonic acid monohydrate (190.2 mg, 1.0 mmol) was added, and the mixture was stirred at rt for 1 h. The additional same acid (190.2 mg, 1.0 mmol) was added to the mixture, and it was stirred at the same temperature for 70 min. To quench the reaction, water and sat. NaHCO~3~ aq. were added to the reaction mixture at rt, successively, and the mixture was extracted with ethyl acetate three times, washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residue by flash column chromatography (hexane/ethyl acetate = 2:1--1:1) afforded **16** (73.5 mg, 71%) as a white powder.

**16**: \[α\]~D~^27^ +38.2 (c 0.69, CHCl~3~); IR (neat) 3405, 1470, 1379, 1163, 992, 942 cm^--1^; ^1^H NMR (600 MHz, CDCl~3~) δ 0.93 (s, 3H), 0.97 (d, *J* = 6.6 Hz, 3H), 1.11--1.69 (m, 20H), 1.79--1.91 (m, 4H), 1.98--2.00 (m, 1H), 4.06--4.07 (m, 1H), 4.86--4.98 (m, 1H); ^13^C NMR (150 MHz, CDCl~3~) δ 13.4, 17.4, 19.1, 22.5, 27.4, 29.6, 29.9, 33.5 (d, *J* = 5.7 Hz), 33.5, 40.3, 41.9, 42.0 (d, *J* = 18.6 Hz), 47.9 (d, *J* = 20.1 Hz), 52.5, 56.9, 69.3, 70.2, 92.3 (d, *J* = 162.3 Hz); HRMS (ESI^+^) calcd for C~18~H~33~O~2~F \[M + Na\]^+^ 323.2357, found 323.2361.

### (1*R*,3*aR*,7*aR*)-1-{(2*R*,4*R*)-4-Fluoro-6-methyl-6-\[(trimethylsilyl)oxy\]heptan-2-yl}-7*a*-methyloctahydro-4*H*-inden-4-one (**7**) {#sec3.1.6}

To the CH~2~Cl~2~ solution (2 mL) of **15** (39.2 mg, 0.13 mmol), 4-methylmorpholine N-oxide (33.8 mg, 0.29 mmol) was added, and the mixture was cooled to 0 °C. To the solution, TPAP (22.9 mg, 0.065 mmol) was added, and it was stirred at 0 °C for 90 min. After dilution with excess Et~2~O, purification of the mixture by flash column chromatography (Et~2~O) gave the crude ketone, which was used for the next step without further purification. TMSCl (35.3 mg, 41 μL, 0.33 mmol) was added to the solution of crude ketone and imidazole (35.4 mg, 0.52 mmol) in CH~2~Cl~2~ (5 mL) at 0 °C. After stirring for 15 min, the reaction was quenched with water at 0 °C, and the mixture was extracted with CH~2~Cl~2~ three times. The organic layer was dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residue by flash column chromatography (hexane/ethyl acetate = 5:1) afforded **7** (28.7 mg, 67%, 2 steps) as a colorless oil.

**7**: \[α\]~D~^27^ −6.6 (c 0.35, CHCl~3~); IR (neat) 1715, 1468, 1382, 1250, 1040, 842 cm^--1^; ^1^H NMR (600 MHz, CDCl~3~) δ 0.11 (s, 9H), 0.66 (s, 3H), 1.11 (dddd, *J* = 1.2, 10.2, 13.8, 40.2 Hz, 1H), 1.26 (s, 3H), 1.30 (s, 3H), 1.31--1.38 (m, 1H), 1.43 (q, *J* = 9.6 Hz, 1H), 1.50--1.63 (m, 4H), 1.66--1.83 (m, 4H), 1.87--1.95 (m, 2H), 2.00--2.04 (m, 1H), 2.13--2.16 (m, 1H), 2.20--2.25 (m, 1H), 2.27--2.31 (m, 1H), 2.45 (dd, *J* = 7.2, 11.4 Hz, 1H), 4.82--4.94 (m, 1H); ^13^C NMR (150 MHz, CDCl~3~) δ 2.6, 12.5, 18.7, 19.1, 24.0, 27.4, 29.2, 31.7, 31.9, 39.0, 41.0, 42.8 (d, *J* = 20.1 Hz), 50.0, 50.5 (d, *J* = 20.1 Hz), 57.0, 62.0, 73.0, 89.1 (d, *J* = 165.1 Hz), 211.9; HRMS (ESI^+^) calcd for C~21~H~39~O~2~FSi \[M + Na\]^+^ 393.2601, found 393.2583.

### (1*R*,3*aR*,7*aR*)-1-{(2*R*,4*S*)-4-Fluoro-6-methyl-6-\[(trimethylsilyl)oxy\]heptan-2-yl}-7*a*-methyloctahydro-4*H*-inden-4-one (**8**) {#sec3.1.7}

To the CH~2~Cl~2~ solution (2 mL) of **16** (34.6 mg, 0.12 mmol), 4-methylmorpholine N-oxide (23.6 mg, 0.20 mmol) was added, and the mixture was cooled to 0 °C. To the solution, TPAP (23.9 mg, 0.068 mmol) was added, and it was stirred at 0 °C for 2 h. After dilution with excess Et~2~O, purification of the mixture by flash column chromatography (Et~2~O) gave the crude ketone, which was used for the next step without further purification. TMSCl (31.3 mg, 36 μL, 0.29 mmol) was added to the solution of crude ketone and imidazole (32.8 mg, 0.48 mmol) in CH~2~Cl~2~ (4 mL) at 0 °C, and the mixture was stirred for 15 min. Additional TMSCl (31.3 mg, 36 μL, 0.29 mmol) was added to the reaction mixture, and it was stirred for 10 min. To quench the reaction, water was added at 0 °C, and the mixture was extracted with CH~2~Cl~2~ three times. The organic layer was dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residue by flash column chromatography (hexane/ethyl acetate = 5:1) gave **8** (28.7 mg, 74%, 2 steps) as a colorless oil.

**8**: \[α\]~D~^27^ +10.3 (c 2.21, CHCl~3~); IR (neat) 1715, 1461, 1382, 1250, 1043, 843 cm^--1^; ^1^H NMR (600 MHz, CDCl~3~) δ 0.10 (s, 9H), 0.65 (s, 3H), 1.03 (d, *J* = 6.0 Hz, 3H), 1.26--1.34 (m, 7H), 1.43--1.77 (m, 9H), 1.85--2.03 (m, 3H), 2.11--2.13 (m, 1H), 2.19--2.29 (m, 2H), 2.45 (dd, *J* = 7.8, 12.0 Hz, 3H), 4.79--4.91 (m, 1H); ^13^C NMR (150 MHz, CDCl~3~) δ 2.5, 13.4, 17.4, 19.1, 22.5, 27.4, 29.6, 29.9, 33.9 (d, *J* = 5.7 Hz), 33.5, 40.3, 41.9, 42.0 (d, *J* = 18.6 Hz), 47.9 (d, *J* = 20.1 Hz), 52.5, 56.9, 69.3, 70.2, 92.3 (d, *J* = 162.3 Hz), 211.9; HRMS (ESI^+^) calcd for C~21~H~39~O~2~FSi \[M + Na\]^+^ 393.2601, found 393.2593.

### (23*R*)-23-Fluoro-25-hydroxyvitamin D~3~ (**5**) {#sec3.1.8}

To the THF solution (2 mL) of **9** (88.2 mg, 0.19 mmol), *n*BuLi (120 μL, 1.6 M hexane solution, 0.19 mmol) was added at −78 °C. After 30 min with stirring, the THF solution (2 mL) of ketone **7** (35.5 mg, 0.096 mmol) was added to the above reaction mixture. The mixture was stirred at −78 °C for 15 min and at 0 °C for 15 min, and then it was allowed to be warmed to rt for 10 min. To quench the reaction, water was added at rt, and the mixture was extracted with ethyl acetate three times, washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residual oil by flash column chromatography (hexane/ethyl acetate = 50:1--1:1) gave the coupling product (45.4 mg). To the THF solution (3 mL) of the above coupling product (45.4 mg), Bu~4~NF (450 μL, 1 M THF solution, 0.45 mmol) was added, and the reaction mixture was stirred at rt for 4 h. To quench the reaction, water was added at rt, and the mixture was extracted with ethyl acetate three times. The combined organic layer was washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residual oil by flash column chromatography (hexane/ethyl acetate = 1:1) afforded **5** (27.1 mg, 68%, in 2 steps) as a white powder.

**5**: \[α\]~D~^27^ +75.3 (c 2.08, EtOH); UV(EtOH) λ~max~ 212.8, 264.2 nm; IR (neat) 3366, 1438, 1380, 1160, 1049, 893 cm^--1^; ^1^H NMR (400 MHz, CD~3~OD) δ 0.62 (s, 3H), 1.07 (d, *J* = 6.4 Hz, 3H), 1.27--2.26 (m, 26H), 2.45 (dt, *J*~(t)~ = 5.0 Hz, *J*~(d)~ = 13.8 Hz, 1H), 2.58 (dd, *J* = 3.7, 12.8 Hz, 1H), 2.89--2.93 (m, 1H), 3.77--3.83 (m, 1H), 4.79 (d, *J* = 1.8 Hz, 1H), 4.83--5.02 (m, 1H), 5.08 (brs, 1H), 6.08 (d, *J* = 11.5 Hz, 1H), 6.26 (d, *J* = 11.5 Hz, 1H); ^13^C NMR (100 MHz, CD~3~OD) δ 12.7, 19.6, 23.58, 24.8, 29.0, 30.2, 31.3, 33.9, 34.1, 36.9, 42.2, 44.5 (d, *J* = 21.0 Hz), 47.3 (d, *J* = 3.8 Hz), 50.6 (d, *J* = 19.1 Hz), 57.8, 58.5, 70.9, 90.2 (d, *J* = 165.0 Hz), 112.9, 119.4, 122.9, 137.7, 142.7, 137.7, 142.7, 147.3; HRMS (ESI^+^) calcd for C~27~H~43~O~2~F \[M + Na\]^+^ 441.3139, found 441.3134.

### (23*S*)-23-Fluoro-25-hydroxyvitamin D~3~ (**6**) {#sec3.1.9}

To the THF solution (2 mL) of **9** (72.3 mg, 0.16 mmol), *n*BuLi (97 μL, 1.6 M hexane solution, 0.15 mmol) was added at −78 °C. After 30 min of stirring, the THF solution (2 mL) of ketone **8** (28.7 mg, 0.077 mmol) was added to the above reaction mixture. The mixture was stirred at −78 °C for 15 min and at 0 °C for 15 min, and then it was allowed to be warmed to rt for 10 min. To quench the reaction, water was added at rt, and the mixture was extracted with ethyl acetate three times, washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residual oil by flash column chromatography (hexane/ethyl acetate = 50:1) gave the coupling product (42.8 mg). To the THF solution (3 mL) of the above coupling product (42.8 mg), Bu~4~NF (424 μL, 1 M THF solution, 0.424 mmol) was added, and the reaction mixture was stirred at rt for 5 h. To quench the reaction, water was added at rt, and the mixture was extracted with ethyl acetate three times. The combined organic layer was washed with sat. NaCl, dried over Na~2~SO~4~, filtered, and concentrated in vacuo. Purification of the residual oil by flash column chromatography (hexane/ethyl acetate = 1:1) gave **6** (13.9 mg, 43%, in 2 steps) as a white powder.

**6**: \[α\]~D~^27^ +55.6 (c 0.54, EtOH); UV(EtOH) λ~max~ 212.6, 264.6 nm; IR (neat) 3377, 1440, 1379, 1265, 1159, 1052, 740 cm^--1^; ^1^H NMR (400 MHz, CD~3~OD) δ 0.62 (s, 3H), 1.07 (d, *J* = 6.4 Hz, 3H), 1.27--1.84 (m, 22H), 1.94--2.26 (m, 6H), 2.45 (dt, *J*~(t)~ = 5.0 Hz, *J*~(d)~ = 13.8 Hz, 1H), 2.58 (dd, *J* = 3.6, 12.4 Hz, 1H), 2.90 (dd, *J* = 4.1, 12.4 Hz, 1H), 3.80 (ddd, *J* = 3.7, 8.7, 12.8 Hz, 1H), 4.78--4.96 (m, 2H), 5.08 (brs, 1H), 6.08 (d, *J* = 11.5 Hz, 1H), 6.26 (d, *J* = 11.0 Hz, 1H); ^13^C NMR (100 MHz, CD~3~OD) δ 12.6, 20.4, 23.6, 24.8, 29.0, 29.2, 30.2, 31.3, 33.9, 35.9 (d, *J* = 5.7 Hz), 36.9, 42.2, 44.0 (d, *J* = 20.0 Hz), 47.3 (d, *J* = 10.5 Hz), 50.1 (d, *J* = 19.7 Hz), 57.8, 58.6, 70.9, 92.3 (d, *J* = 164.9 Hz), 113.0, 119.4, 122.9, 137.7, 142.7, 147.3; HRMS (ESI^+^) calcd for C~27~H~43~O~2~F \[M + Na\]^+^ 441.3139, found 441.3141.

### Metabolism of 25(OH)D~3~ and Its Analogues by Human CYP24A1 {#sec3.1.10}

The metabolism of 25(OH)D~3~ and its analogues **5** and **6** by CYP24A1 were analyzed using the membrane fraction prepared from recombinant *Escherichia coli* cells expressing human CYP24A1 as described in our previous study.^[@ref14]^ Briefly, the reaction mixture containing 0.02 μM human CYP24A1, 2.0 μM adrenodoxin (ADX), 0.2 μM NADPH--adrenodoxin reductase (ADR), 0.2--6.0 μM each substrate, 1.0 mM NADPH, 100 mM Tris--HCl (pH 7.4), and 1 mM EDTA was incubated at 37 °C for 1--10 min. The metabolites were extracted with 4 volumes of CHCl~3~--CH~3~OH (3:1) and analyzed by reversed-phase HPLC under the following conditions: column, CAPCELL PAK C18 UG120 (5 μm) (4.6 mm × 250 mm) (SHISEIDO, Tokyo, Japan); UV detection, 265 nm; flow rate, 1.0 mL/min; column temperature, 40 °C; mobile phase, CH~3~CN: a linear gradient of 20--100% CH~3~CN aqueous solution per 25 min and 100% CH~3~CN for 10 min. Kinetic parameters, *K*~m~ and *k*~cat~ were calculated by the nonlinear regression analysis using KaleidaGraph (Synergy Software, Reading, PA). The equation was applied for Michaelis--Menten kinetics.
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